High-dose-intensity combination chemotherapy for advanced sarcomas: A pilot study

Paolo Pronzato, Pierluigi Losardo, Floriana Pensa, Alessandra Tognoni

Research output: Contribution to journalArticlepeer-review


A new polychemotherapy schedule involving high dose intensity and shortened intervals has been developed patients with advanced sarcomas. Mesna at 2500 mg/m 2 for 3 days, epidoxorubicin at 60 mg/m 2 on day 1, ifosfamide at 2500 mg/m 2 for 3 days, and dacarbazine at 450 mg/m 2 for 2 days were given every 2 weeks to a consecutive series of 20 patients. All patients received granulocyte colony-stimulating factor (CG-CSF; Filgrastim) subcutaneously at 300 μg from day 5 to day 12 of each cycle. The treatment was feasible and toxicity was acceptable, with grade IV myelotoxicity being observed only in one case. In all, 6 of 14 evaluable patients had an objective response; the median survival was 12 months. Toxicity was milder than that observed for the classic combination MAID, and the planned dose intensity was maintained in the majority of cases.

Original languageEnglish
Pages (from-to)513-516
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number6
Publication statusPublished - 1998


  • Chemotherapy dose intensity
  • G-CSF
  • Sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology


Dive into the research topics of 'High-dose-intensity combination chemotherapy for advanced sarcomas: A pilot study'. Together they form a unique fingerprint.

Cite this